IGF2BP2 Facilitates DDP Resistance in NSCLC Through Stabilizing SEZ6L2 Expression
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Zhuoyu Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Shunde Hospital Guangzhou University of Chinese Medicine, Foshan City, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, RNA-Binding Proteins, Drug Resistance, Neoplasm. Die Arbeit nennt 37 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) is a type of lung cancer, patients with which harbor poor overall survival. Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) is an RNA‐binding protein, and its mechanism of action in DDP‐resistant NSCLC has not been reported. Quantitative real‐time PCR (qRT‐PCR) and western blot were used to detect gene and protein expression. DDP‐resistant NSCLC cells were established to study the function of IGF2BP2 in vitro by Cell Counting Kit‐8 (CCK‐8), colony formation, wound healing, transwell, flow cytometry, and tube formation assays. Seizure related 6 homolog like 2 (SEZ6L2) was identified as the target, and the interaction between IGF2BP2 and SEZ6L2 were predicted by online websites, which was confirmed by RNA immunoprecipitation (RIP), and dual luciferase reporter assay, and RNA decay assay. In vivo , DDP‐resistant cell‐derived xenograft mice models were used to verify the effects of IGF2BP2 on tumor growth. IGF2BP2 was upregulated in DDP‐resistant NSCLC patients and cells, which represented a poor prognosis. The silence of IGF2BP2 blocked proliferation, migration, and invasion of DDP‐resistant NSCLC cells and accelerated apoptosis. Meanwhile, IGF2BP2 knockdown retarded the angiogenesis and macrophage M2 polarization. Furthermore, SEZ6L2 was highly expressed in DDP‐resistant NSCLC patients and cells, and the patients with SEZ6L2 high expression had poor prognosis. Mechanistically, IGF2BP2 mediated the N6‐methyladenosine (m6A) methylation and expression of SEZ6L2. Moreover, the inhibitory effects of IGF2BP2 silence on DDP‐resistant NSCLC cell malignant behaviors were weakened by SEZ6L2 overexpression. The knockdown of IGF2BP2 also confined the tumor growth in vivo. In the present study, IGF2BP2 promotes the progression of DDP‐resistant NSCLC by mediating m6A methylation on SEZ6L2 mRNA, providing a certain reference for the treatment of DDP‐resistant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Shunde Hospital Guangzhou University of Chinese Medicine, Foshan City, China.
- Department of Oncology, Shunde Hospital Guangzhou University of Chinese Medicine, Foshan City, China.
ORCID-Profile: Guoping Luo
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Chen, Z., Yang, Z., Chen, N., & Luo, G. (2025). IGF2BP2 Facilitates DDP Resistance in NSCLC Through Stabilizing SEZ6L2 Expression. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70430
Vancouver
Chen Z, Yang Z, Chen N, Luo G. IGF2BP2 Facilitates DDP Resistance in NSCLC Through Stabilizing SEZ6L2 Expression. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70430
BibTeX
@article{Chen2025,
author = {Chen, Zhuoyu and Yang, Zhaoqiang and Chen, Nan and Luo, Guoping},
title = {IGF2BP2 Facilitates DDP Resistance in NSCLC Through Stabilizing SEZ6L2 Expression},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70430}
}
EUVIMED